199 related articles for article (PubMed ID: 32227266)
1. Radiomics of cholangiocarcinoma on pretreatment CT can identify patients who would best respond to radioembolisation.
Mosconi C; Cucchetti A; Bruno A; Cappelli A; Bargellini I; De Benedittis C; Lorenzoni G; Gramenzi A; Tarantino FP; Parini L; Pettinato V; Modestino F; Peta G; Cioni R; Golfieri R
Eur Radiol; 2020 Aug; 30(8):4534-4544. PubMed ID: 32227266
[TBL] [Abstract][Full Text] [Related]
2. Yttrium-90 microsphere radioembolization in unresectable intrahepatic cholangiocarcinoma.
Mosconi C; Cappelli A; Ascanio S; Pettinari I; Modestino F; Renzulli M; Galaverni MC; Cucchetti A; Gramenzi A; Pettinato C; Golfieri R
Future Oncol; 2017 Jun; 13(15):1301-1310. PubMed ID: 28343412
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Choi criteria and Response Evaluation Criteria in Solid Tumors (RECIST) for intrahepatic cholangiocarcinoma treated with glass-microspheres Yttrium-90 selective internal radiation therapy (SIRT).
Beuzit L; Edeline J; Brun V; Ronot M; Guillygomarc'h A; Boudjema K; Gandon Y; Garin E; Rolland Y
Eur J Radiol; 2016 Aug; 85(8):1445-52. PubMed ID: 27423686
[TBL] [Abstract][Full Text] [Related]
4. Preliminary experience with CT-guided high-dose rate brachytherapy as an alternative treatment for hepatic recurrence of cholangiocarcinoma.
Kamphues C; Seehofer D; Collettini F; Bahra M; Neuhaus P; Wust P; Denecke T; Gebauer B; Schnapauff D
HPB (Oxford); 2012 Dec; 14(12):791-7. PubMed ID: 23134179
[TBL] [Abstract][Full Text] [Related]
5. A radiomic-based model of different contrast-enhanced CT phase for differentiate intrahepatic cholangiocarcinoma from inflammatory mass with hepatolithiasis.
Xue B; Wu S; Zhang M; Hong J; Liu B; Xu N; Zeng Q; Tang K; Zheng X
Abdom Radiol (NY); 2021 Aug; 46(8):3835-3844. PubMed ID: 33728532
[TBL] [Abstract][Full Text] [Related]
6. Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis.
Iavarone M; Piscaglia F; Vavassori S; Galassi M; Sangiovanni A; Venerandi L; Forzenigo LV; Golfieri R; Bolondi L; Colombo M
J Hepatol; 2013 Jun; 58(6):1188-93. PubMed ID: 23485522
[TBL] [Abstract][Full Text] [Related]
7. Predictability of the radiological response to Yttrium-90 transarterial radioembolization by dynamic magnetic resonance imaging-based radiomics analysis in patients with intrahepatic cholangiocarcinoma.
Ballı HT; Pişkin FC; Püren Yücel S; Sözütok S; Özgül D; Aikimbaev K
Diagn Interv Radiol; 2024 May; 30(3):193-199. PubMed ID: 36994655
[TBL] [Abstract][Full Text] [Related]
8. A radiomics approach to predict lymph node metastasis and clinical outcome of intrahepatic cholangiocarcinoma.
Ji GW; Zhu FP; Zhang YD; Liu XS; Wu FY; Wang K; Xia YX; Zhang YD; Jiang WJ; Li XC; Wang XH
Eur Radiol; 2019 Jul; 29(7):3725-3735. PubMed ID: 30915561
[TBL] [Abstract][Full Text] [Related]
9. Differentiation of small intrahepatic mass-forming cholangiocarcinoma from small liver abscess by dual source dual-energy CT quantitative parameters.
Kim JE; Kim HO; Bae K; Cho JM; Choi HC; Choi DS
Eur J Radiol; 2017 Jul; 92():145-152. PubMed ID: 28624012
[TBL] [Abstract][Full Text] [Related]
10. Predicting IDH mutation status of intrahepatic cholangiocarcinomas based on contrast-enhanced CT features.
Zhu Y; Chen J; Kong W; Mao L; Kong W; Zhou Q; Zhou Z; Zhu B; Wang Z; He J; Qiu Y
Eur Radiol; 2018 Jan; 28(1):159-169. PubMed ID: 28752218
[TBL] [Abstract][Full Text] [Related]
11. Differentiation of mass-forming intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma: based on the multivariate analysis of contrast-enhanced computed tomography findings.
Zhao YJ; Chen WX; Wu DS; Zhang WY; Zheng LR
Abdom Radiol (NY); 2016 May; 41(5):978-89. PubMed ID: 27193795
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Yttrium-90 Transarterial Radioembolization with Resin Microspheres Prescribed Using the Medical Internal Radiation Dose Model for Intrahepatic Cholangiocarcinoma.
Sarwar A; Ali A; Ljuboja D; Weinstein JL; Shenoy-Bhangle AS; Nasser IA; Morrow MK; Faintuch S; Curry MP; Bullock AJ; Ahmed M
J Vasc Interv Radiol; 2021 Nov; 32(11):1560-1568. PubMed ID: 34454031
[TBL] [Abstract][Full Text] [Related]
13. Distinguishing intrahepatic mass-forming biliary carcinomas from hepatocellular carcinoma by computed tomography and magnetic resonance imaging using the Bayesian method: a bi-center study.
Ichikawa S; Isoda H; Shimizu T; Tamada D; Taura K; Togashi K; Onishi H; Motosugi U
Eur Radiol; 2020 Nov; 30(11):5992-6002. PubMed ID: 32500195
[TBL] [Abstract][Full Text] [Related]
14. Factors Impacting Survival After Transarterial Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Combined Analysis of the Prospective CIRT Studies.
Reimer P; Vilgrain V; Arnold D; Balli T; Golfieri R; Loffroy R; Mosconi C; Ronot M; Sengel C; Schaefer N; Maleux G; Munneke G; Peynircioglu B; Sangro B; Kaufmann N; Urdaniz M; Pereira H; de Jong N; Helmberger T
Cardiovasc Intervent Radiol; 2024 Mar; 47(3):310-324. PubMed ID: 38321223
[TBL] [Abstract][Full Text] [Related]
15. Mass-forming intrahepatic cholangiocarcinoma with marked enhancement on arterial-phase computed tomography reflects favorable surgical outcomes.
Ariizumi S; Kotera Y; Takahashi Y; Katagiri S; Chen IP; Ota T; Yamamoto M
J Surg Oncol; 2011 Aug; 104(2):130-9. PubMed ID: 21448898
[TBL] [Abstract][Full Text] [Related]
16. Delayed-phase dynamic CT enhancement as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma.
Asayama Y; Yoshimitsu K; Irie H; Tajima T; Nishie A; Hirakawa M; Nakayama T; Kakihara D; Taketomi A; Aishima S; Honda H
Radiology; 2006 Jan; 238(1):150-5. PubMed ID: 16304089
[TBL] [Abstract][Full Text] [Related]
17. Computed tomography-guided interstitial HDR brachytherapy (CT-HDRBT) of the liver in patients with irresectable intrahepatic cholangiocarcinoma.
Schnapauff D; Denecke T; Grieser C; Collettini F; Seehofer D; Sinn M; Banzer J; Lopez-Hänninen E; Hamm B; Wust P; Gebauer B
Cardiovasc Intervent Radiol; 2012 Jun; 35(3):581-7. PubMed ID: 21833806
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral artery on contrast-enhanced computed tomography imaging: differentiating intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma.
Tsunematsu S; Chuma M; Kamiyama T; Miyamoto N; Yabusaki S; Hatanaka K; Mitsuhashi T; Kamachi H; Yokoo H; Kakisaka T; Tsuruga Y; Orimo T; Wakayama K; Ito J; Sato F; Terashita K; Nakai M; Tsukuda Y; Sho T; Suda G; Morikawa K; Natsuizaka M; Nakanishi M; Ogawa K; Taketomi A; Matsuno Y; Sakamoto N
Abdom Imaging; 2015 Aug; 40(6):1492-9. PubMed ID: 25579172
[TBL] [Abstract][Full Text] [Related]
19. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival.
Hoffmann RT; Paprottka PM; Schön A; Bamberg F; Haug A; Dürr EM; Rauch B; Trumm CT; Jakobs TF; Helmberger TK; Reiser MF; Kolligs FT
Cardiovasc Intervent Radiol; 2012 Feb; 35(1):105-16. PubMed ID: 21431970
[TBL] [Abstract][Full Text] [Related]
20. Computed Tomography Radiomics to Differentiate Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma.
Mahmoudi S; Bernatz S; Ackermann J; Koch V; Dos Santos DP; Grünewald LD; Yel I; Martin SS; Scholtz JE; Stehle A; Walter D; Zeuzem S; Wild PJ; Vogl TJ; Kinzler MN
Clin Oncol (R Coll Radiol); 2023 May; 35(5):e312-e318. PubMed ID: 36804153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
